Month: March 2026

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) — Anbio Biotechnology (NASDAQ: NNNN) (“Anbio” or the “Company”), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026. Anbio’s CEO is scheduled to participate in a fireside chat and will have the opportunity to share the Company’s previously disclosed business updates, strategic initiatives, and product development with the investor community. Anbio’s participation in the conference reflects the Company’s continued engagement with the investment community and supports its commitment to broadening access to rapid diagnostics, advancing its innovative product pipeline, and creating long-term value...

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melanoma (mUM), at the 2026 American Association for Cancer Research (AACR) Annual Meeting commencing on April 17, 2026. The Company will issue...

Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer) Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meetingCOPENHAGEN, Denmark, March 17, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces two abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California, April 17-22, 2026. One abstract will include new biomarker and immunogenicity data for...

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. “We are excited to highlight the potential to expand the opportunity for azenosertib as a combination therapy...

– Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways – NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours resulted...

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California. Poster Presentation Details Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alphaPoster/Abstract: 2950Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer DrugsDate/Time: April 20, 2026, from 2:00-5:00pm PT / 5:00pm-8:00pm ET Title: Palazestrant, a CERAN, in combination with...

FREEHOLD, NJ, March 17, 2026 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced today that it has published its 2025 Annual Report. It is now available on the Company’s website at www.umh.reit. Samuel A. Landy, President and Chief Executive Officer, commented, “We are proud to announce that our 2025 Annual Report is now available on our website. We encourage everyone to read our Annual Report to gain further information on our Company and our future outlook.” UMH Properties, Inc., which was organized in 1968, is a public equity REIT that currently owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,000 contain rental homes, and over 1,000 self-storage...

CHANTILLY, Va., March 17, 2026 (GLOBE NEWSWIRE) — Today, Parsons Corporation (NYSE: PSN) announced a planned transition in its human resources function leadership, promoting Soo Lagasse to chief human resources officer (CHRO), effective April 1, 2026. Lagasse, who currently serves as senior vice president of global talent acquisition and mobility at Parsons, succeeds Susan Balaguer, who notified Parsons’ CEO and board of directors of her intent to retire this spring. Balaguer will remain with Parsons through the end of May to ensure a seamless transition. “Susan Balaguer transformed Parsons’ human resources enterprise over the last four and a half years and set it on a trajectory to ensure we truly exemplify our People First culture,” said Carey Smith, Parsons’ chair, president, and chief executive officer. “From aligning our benefits...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA. Details of the presentations at AACR 2026: Logic-gated Switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancerSession Category: ImmunologySession Title: T Cell Engagers 1Session Start: 4/20/2026 9:00 AM PTSession End: 4/20/2026 12:00 PM PTLocation: Poster Section 10Poster Board Number: 16Poster...

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) granted equity awards to two newly hired employees in the form of restricted stock units (“RSUs”) and non-qualified stock options (“NSOs”) for an aggregate of 38,442 RSUs and 43,000 NSOs as an inducement material to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The employment inducement awards were granted under the Company’s 2025 Inducement Plan. Each NSO has an exercise price equal to $6.20 per share, the closing price on March 16, 2026. The NSOs will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting...